Savara Resubmits Molbreevi BLA for Rare Lung Disease Treatment with Priority Review Request.

Savara has resubmitted its Biologics License Application for Molbreevi to the FDA for treating autoimmune pulmonary alveolar proteinosis. Fujifilm is designated as the manufacturer, and the company has applied for a Priority Review. Despite challenges in financial metrics, Savara boasts strong liquidity and conservative debt management. Valuation metrics suggest a high-risk, high-reward investment with institutional confidence, but recent insider selling may raise concerns. Technical indicators show a positive short-term trend. Investors should consider financial health, volatility, and sector-specific risks.